TIVDAK: payments to doctors
Payments that named TIVDAK as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $4.4M
- Providers
- 6,231
- Transactions
- 18,516
- Average per transaction
- $235
The per-transaction average — $235 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 6,231 providers the average total is $699, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Seagen Inc. | $2,052,315 | 47.1% |
| Genmab U.S., Inc. | $1,504,217 | 34.5% |
| Pfizer | $788,661 | 18.1% |
| Genmab A/s | $9,280 | 0.2% |
| Array Biopharma Inc | $467 | 0.0% |